In the absence of randomized, controlled trial data to support iron chelation therapy in transfusion-dependent patients with myelodysplastic syndromes (MDS), continued evidence from large prospective clinical trials evaluating the efficacy and safety of iron chelation therapy in this patient population is warranted.
Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial) / Angelucci E1; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S.. - In: EUROPEAN JOURNAL OF HAEMATOLOGY. - ISSN 0902-4441. - ELETTRONICO. - 92:(2014), pp. 527-536. [10.1111/ejh.12300]
Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
SANTINI, VALERIA;
2014
Abstract
In the absence of randomized, controlled trial data to support iron chelation therapy in transfusion-dependent patients with myelodysplastic syndromes (MDS), continued evidence from large prospective clinical trials evaluating the efficacy and safety of iron chelation therapy in this patient population is warranted.File | Dimensione | Formato | |
---|---|---|---|
angelucci2014.pdf
accesso aperto
Descrizione: Articolo
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
170.43 kB
Formato
Adobe PDF
|
170.43 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.